YOLT-203 treatment study for primary hyperoxaluria type 1
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new drug called YOLT-203 for people with primary hyperoxaluria type 1 (PH1), a rare genetic condition where the body produces too much oxalate, which can damage the kidneys. The trial aims to see if this drug can help reduce oxalate levels and prevent kidney damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 6 years old
- You have been diagnosed with PH1 through genetic testing
- Your urine oxalate levels are higher than normal (confirmed by at least two 24-hour urine tests)
- If you take vitamin B6, your dose has been stable for at least 3 months and you can keep it the same during the study
- You are willing to follow all study procedures and sign a consent form (parent/guardian signature required if under 18)
- You can commit to standard PH1 care including drinking plenty of fluids, taking prescribed medications, and following dietary advice
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment for primary hyperoxaluria type 1, a rare condition that causes too much oxalate in the body, which can lead to kidney stones and kidney damage. The treatment is given as an injection, and the study will see if it is safe and how the body responds.
This Phase 2 study tests a medicine called DCR-PHXC to lower body oxalate levels in people with PH1 who have advanced kidney failure. By lowering oxalate, the treatment may reduce harm from oxalate buildup and help researchers understand safety and effectiveness.
This trial tests a medication called stiripentol to see if it can lower oxalate levels in people with primary hyperoxaluria (types 1, 2, or 3). It may help prevent kidney stones and protect kidney function.
This study is for people with certain rare kidney conditions that can cause kidney stones. It aims to learn how these conditions behave over time and may help improve future care.
This study looks at how the body reacts to oxalate in people with calcium oxalate kidney stones and in people without kidney stones. It may help researchers understand why some people form stones and how to better prevent them.
This trial studies whether VX-147 can improve kidney disease caused by an APOL1 gene change, which often leads to protein leaking into the urine. It includes both adults and children and focuses on safety and effectiveness over time.
Hear when a new Primary Hyperoxaluria Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.